RESUMEN
BACKGROUND: Despite extensive research, the pathophysiology of Charcot foot is still not fully understood. In the case of late diagnosis and insufficient therapy, severe deformity may occur. OBJECTIVES: Different theories on the pathophysiology of the Charcot foot are presented and discussed. MATERIALS AND METHODS: This article presents different theories on the pathophysiology of the Charcot foot and presents studies on the cellular, immunological, and bone metabolism level. RESULTS: One theory is based on repetitive microtraumas in the sensoric deficient foot which lead to development of Charcot foot. Another theory is based on pathologic neurovascular innervation leading to morphologic changes. Probably both mechanisms are responsible in combination as etiological factors inducing neuropathy CONCLUSION: A combination of mechanical, vascular, and biologic factors induce the neuropathic foot and result in severe deformity if diagnosis is too late.
Asunto(s)
Artropatía Neurógena/inmunología , Pie Diabético/inmunología , Deformidades del Pie/inmunología , Traumatismos de los Pies/inmunología , Modelos Inmunológicos , HumanosAsunto(s)
Absidia , Traumatismos de los Pies/microbiología , Huésped Inmunocomprometido , Leucemia Mieloide Aguda/complicaciones , Mucormicosis/inmunología , Anciano , Antifúngicos/uso terapéutico , Complicaciones de la Diabetes/microbiología , Traumatismos de los Pies/inmunología , Humanos , Leucemia Mieloide Aguda/inmunología , Masculino , Pirimidinas/uso terapéutico , Triazoles/uso terapéutico , VoriconazolRESUMEN
This study was aimed to evaluate the therapeutic potency of a new antimalarial drug, artesunate, in an experimental model of rheumatoid arthritis. Collagen-induced arthritis (CIA) was induced in Lewis rats.The intraperitoneally administration of artesunate (ARS) and methotrexate (MTX) were started on day 25 postimmunization and continued until final assessment on day 35. During this period, clinical examination was intermittent. The anticollagen type II antibody (CII Ab) and nitric oxide synthesis were measured. The paws and kness were then removed for histopathology and radiography assay. The biocompatibility of ARS and MTX were assessed using fibrosarcoma cell line. Our results showed that i.p. injection of artesunate to arthritic rats induced a significant reduction in paw edema. This beneficial effect was associated with a significant decrease in anti-CII antibody response compared with untreated rats. Histopathological assessment showed reduced inflammatory cells infiltrate in joints of treated rats, and tissue edema and bone erosion in the paws were markedly reduced following ARS therapy. Moreover, our radiographic results paralleled histological findings. Cytotoxicity analysis of ARS showed greater tolerability compared with MTX. Treatment with ARS significantly diminished nitric oxide formation in treated rats compared with untreated controls. Our findings revealed the therapeutic efficacy of artesunate in experimental rheumatoid arthritis compared with a choice drug (methotrexate). This result may recommend it as a second-line drug in the treatment of rheumatoid arthritis.